이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

절제 불가능한 간세포암종에 대한 광자 방사선요법을 병용한 아테졸리주맙 및 베바시주맙 (PhotonAB)

2026년 9월 28일 업데이트: Chang Gung Memorial Hospital

아테졸리주맙과 베바시주맙을 병용한 광자 방사선 치료를 받는 절제 불가능한 간세포암종 환자의 항종양 면역 반응에 대한 조사

Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) in conjunction with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) has become the established standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). Despite an improved objective response rate (ORR) of 27%, the majority of patients face HCC progression and liver failure [Finn et al., N Engl J Med 2020]. Developing a new combined treatment strategy to overcome resistance to anti-PD-L1 and anti-VEGF is essential to improve patient outcomes.

Radiation treatment (RT) is highly efficacious in controlling localized solid tumors and has become an integral component of the treatment algorithm for unresectable HCC. Importantly, a recent retrospective cohort described that RT combined with atezolizumab plus bevacizumab was associated with favorable median overall survival of 16.1 months (Manzar et al, Cancers 2022). Our preclinical study (Hsieh et al., Science Immunology 2022) revealed that RT combined with PD-L1/PD-1 blockade induces immunogenic cell death and tumor antigen cross-presentation in antigen-presenting cells, thereby potentiating the systemic antitumor T cell responses in murine tumor models. However, whether the combinatorial therapy with RT, atezolizumab, and bevacizumab can trigger synergistic antitumor effects and systemic immune mobilization has not yet been validated in clinical trials for unresectable HCC.

Both atezolizumab/bevacizumab and X-ray RT are approved treatment methods for unresectable HCC by the U.S. and Taiwan Food and Drug Administration (FDA). The present phase II non-randomized trial aims to prospectively document the therapeutic efficacy, safety, and immunological responses in patients with unresectable HCC treated with atezolizumab/bevacizumab combined with conventional photon radiotherapy.

연구 개요

연구 유형

중재적

등록 (추정된)

45

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Rodney Cheng-En Hsieh, MD, PhD
  • 전화번호: 7000 +886-3-3281200
  • 이메일: rodney445@gmail.com

연구 장소

    • Taiwan
      • Taoyuan City, Taiwan, 대만, 333
        • 모병
        • Chang Gung Memorial Hospital at Linkou
        • 연락하다:
          • Rodney Cheng-En Hsieh, MD, PhD
          • 전화번호: 7000 +88633281200
          • 이메일: rodney445@gmail.com

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Participants must have a diagnosis of HCC that is deemed unsuitable for surgical resection or transplant. Participants may have multiple lesions with a total maximal tumor dimension of < 20 cm, and no one lesion > 15 cm. Diagnosis should be confirmed by at least 1 criterion listed below:

    • Histologically or cytologically proven diagnosis of HCC.
    • Typical arterial enhancement and delayed washout on multiphasic CT or MRI.
  2. Age ≥18 years at the time of signing the informed consent document.

  3. ECOG performance status 0-1.

  4. Barcelona Clinic Liver Cancer (BCLC) stages Intermediate (B) or Advanced (C).

  5. Child-Pugh score 5-6 liver function within 28 days of study registration.

  6. Documented virology status of hepatitis B virus (HBV), as confirmed by screening HBV serology test.

  7. Documented virology status of hepatitis C virus (HCV), as confirmed by screening HCV serology test.

  8. Ability to understand and the willingness to sign a written informed consent document

  9. Adequate bone marrow, liver, and renal function within 4 weeks before study registration

    • Hemoglobin ≥ 9.0 g/dL
    • Absolute neutrophil count (ANC) ≥ 1,000/mm3
    • Platelet count ≥ 50,000/μL
    • Total bilirubin < 2.5 mg/dL
    • Serum albumin >2.8 g/dL
    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN)
    • Prothrombin time ≤ 6 seconds prolonged
    • Serum creatinine ≤ 1.5 mg/dL

Exclusion Criteria:

  1. Prior invasive malignancy unless disease-free for a minimum of 2 years

  2. Prior radiotherapy to the region of the liver that would result in overlap of radiation therapy fields

  3. Prior selective internal radiotherapy/hepatic arterial yttrium therapy, at any time

  4. Untreated active hepatitis B or hepatitis C

  5. Moderate to severe or intractable ascites

  6. Presence of distant metastases that cannot be encompassed by photon radiotherapy

  7. Untreated or incompletely treated esophageal or gastric varices

  8. Severe, active co-morbidity, defined as follows:

    • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration
    • Myocardial infarction within the last 6 months prior to study entry
    • Acute bacterial or fungal infection requiring intravenous antibiotics within 28 days prior to study entry
    • A bleeding episode within 6 months prior to study entry due to any cause.
    • Thrombolytic therapy within 28 days prior to study entry.
    • Known bleeding or clotting disorder.
    • Uncontrolled psychotic disorder
  9. Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception

  10. Prior solid organ transplantation.

  11. Prior or active autoimmune disease (AID) including autoimmune hepatitis, inflammatory bowel disease, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, and multiple sclerosis.

  12. Prior or active thrombotic or bleeding disorders, hemoptysis, cerebral vascular accident, significant cardiac disease (ischemic or congestive heart failure), or gastrointestinal perforation.

  13. Inability to treat all sites of disease by photon radiotherapy (such as extrahepatic metastases or massive liver tumors whereby the liver constraints cannot be met for covering all sites of liver tumors.)

  14. Known HIV infection.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Atezolizumab and bevacizumab with photon radiotherapy

Patients undergo Atezolizumab and Bevacizumab with photon radiotherapy.

Atezolizumab 1200 mg will be administered as an IV infusion on Day 1 of each cycle, with cycles occurring every 3 weeks. The initial dose will be delivered over 60 (± 15) minutes, and if well-tolerated, subsequent infusions may be given over 30 minutes. For patients who achieve a complete response (CR) within one year of treatment, atezolizumab should be continuously used for a year. For patients who experience a partial response (PR), atezolizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive atezolizumab for 6 months. In the case of PD, atezolizumab should be discontinued at the time when PD is confirmed.

Bevacizumab 15 mg/kg will be administered as an IV infusion on Day 1 of each 3-week cycle. The initial dose will be delivered over 90 minutes (±15 minutes), and if well-tolerated, subsequent infusions may be given over 60 minutes. For patients who achieve a complete response (CR) within one year of treatment, bevacizumab should be continuously used for a year. In the case of patients experiencing a partial response (PR), bevacizumab should be continued until achieving CR or experiencing progressive disease (PD). Patients with stable disease should receive bevacizumab for 6 months. In the event of PD, bevacizumab should be discontinued when PD is confirmed. Temporary withholding or dose reduction of bevacizumab is permitted if patients experience adverse events such as bleeding episodes, severe hypertension, or proteinuria at the discretion of the treating physician.

  • 39.6-72.6 Gy in 22 fractions for tumors ≤1 cm from the hepatic hilum, bowel, and heart.
  • 30-66 Gy in 10 fractions for tumors >1 cm from the hepatic hilum, bowel, and heart.
  • 27.5-50 Gy in 5 fractions using stereotactic body radiation therapy (SBRT) techniques

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression free survival (PFS)
기간: 12 months

PFS is defined as the time from signing the informed consent to the first occurrence of disease progression or death from any cause (whichever occurs first) according to RECIST1.1.

12 months

2차 결과 측정

결과 측정
측정값 설명
기간
Local control (LC)
기간: 12 months

LC is defined as the time from signing the informed consent to the first occurrence of disease progression in the irradiated field according to RECIST1.1.

12 months
Time to progression (TTP)
기간: 12 months

TTP is defined as the time from signing the informed consent to the first occurrence of disease progression according to RECIST1.1.

12 months
Overall Response Rate (ORR)
기간: 12 months

ORR is defined as a complete or partial response according to RECIST1.1.

12 months
Overall survival (OS)
기간: 12 months

OS is defined as the time from signing the informed consent to death from any cause.

12 months
Incidence and severity of adverse events
기간: 12 months

Adverse events will be graded using CTCAE v5

12 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 3월 30일

기본 완료 (추정된)

2029년 3월 30일

연구 완료 (추정된)

2031년 3월 30일

연구 등록 날짜

최초 제출

2024년 3월 25일

QC 기준을 충족하는 최초 제출

2024년 3월 25일

처음 게시됨 (실제)

2024년 4월 1일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 1일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 28일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Sharing individual participant data (IPD) with other researchers requires IRB review and approval. Presently, we do not have a plan to provide IPD to other researchers

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다